The history and neurologic assessment data should be obtained within minutes of the patient's arrival, and the clinical decision point is the 4.5-hour intravenous thrombolysis window from last known well, with the full diagnostic workup completed inside 60 minutes of arrival under guidelines issued by the American Heart Association and American Stroke Association. The single most important time anchor is not arrival at the hospital but the last time the patient was seen neurologically normal. Every clock in the assessment starts there. In hyperacute stroke care, the standard published target is a door-to-needle time of 60 minutes or less, and guideline authors have argued that 45 minutes or less is achievable for most patients.
The Four Time Anchors That Govern When Assessment Data Must Be Collected
Four separate clocks run simultaneously in acute stroke care, and each one sets a different deadline for obtaining history and neurologic data. The first is last known well, the moment the patient was last witnessed or reported to be at neurologic baseline. The second is door time, the moment the patient arrives at the treating facility. The third is imaging time, when the CT scan is completed. The fourth is needle or groin-puncture time, when treatment begins.
Last known well is the enforceable medical-legal anchor. If a patient wakes with symptoms at 6:00 a.m. but was normal at 11:00 p.m. the night before, the clock for thrombolysis eligibility began at 11:00 p.m., so more than seven hours have already elapsed by the time of arrival. History-taking must establish this timestamp before nearly any other question, because it determines whether the patient is inside or outside the treatment window.
Door time drives the performance metrics that hospitals are measured against. The Joint Commission and the American Heart Association's Get With The Guidelines–Stroke program track door-to-CT and door-to-needle intervals, and hospitals report these internally as quality measures. A facility that consistently exceeds 60 minutes door-to-needle faces internal review, which means the assessment data that feeds the decision gets collected on a strict sequence rather than in a leisurely order.
Imaging time and treatment time are downstream, but they feed back into history-taking. If the non-contrast CT shows no hemorrhage, the history questions sharpen toward absolute and relative contraindications for thrombolysis. If it shows a large vessel occlusion, the questions shift toward thrombectomy eligibility, which in selected patients extends to 24 hours from last known well under the DEFUSE 3 and DAWN trial criteria.
The practical consequence is that the four clocks do not sequence neatly. They overlap, and the assessment must be built to collect the right data at the right moment rather than to complete a form in order.
Why Last Known Well Beats Symptom Onset Every Single Time
Symptom onset is the wrong anchor for most patients, and getting this wrong is the most common reason a treatable patient is excluded. Roughly a quarter to a third of ischemic stroke patients wake with their deficits, which means the exact onset moment is unknowable. For those patients, last known well is the only defensible timestamp.
A patient who went to bed at 10:00 p.m. feeling fine and woke at 7:00 a.m. with a facial droop has a last known well of 10:00 p.m., not 7:00 a.m. Under the 4.5-hour intravenous alteplase window, that patient is outside the standard window by the time of arrival. Under extended-window protocols using perfusion imaging, that patient may still qualify for thrombectomy, but only if the appropriate imaging and history are collected.
The distinction matters because failing to establish last known well early forces the team to treat the patient conservatively. Anecdotally, emergency clinicians describe the scenario repeatedly: a family member says "it started this morning," the team documents "onset this morning," and the actual last known well was the previous evening. That documentation error can cost the patient a treatment option.
When no reliable witness exists, the standard is to treat the time the patient was last seen normal as the onset, and to document the uncertainty explicitly. Some centers also apply the "wake-up stroke" imaging pathway, using MRI DWI-FLAIR mismatch or CT perfusion to identify patients who may still benefit despite an unknown onset time. That pathway was validated in the WAKE-UP trial, published in the New England Journal of Medicine in 2018.
The 4.5-Hour Window and the Questions That Must Be Answered Inside It
Intravenous thrombolysis with alteplase is approved for use up to 4.5 hours from last known well in eligible patients, and tenecteplase has been evaluated in the same window, with the American Heart Association's 2019 guideline update endorsing tenecteplase as a reasonable alternative to alteplase in selected patients. Inside that window, several history elements must be collected before the drug goes in.
The critical history items are anticoagulant use with the last dose and timing, recent surgery or invasive procedure within 14 days, prior intracranial hemorrhage, known bleeding disorder, recent gastrointestinal or urinary bleeding, uncontrolled hypertension, seizure at onset, and recent myocardial infarction. Each of these is a potential exclusion or a trigger for additional testing. The blood glucose must be checked before treatment because hypoglycemia can mimic stroke and is corrected rather than thrombolysed.
The neurologic assessment data that must be captured inside the window includes the NIH Stroke Scale score, which quantifies deficit severity on a 0–42 scale and is required for treatment decisions and outcome tracking. The score must be documented before treatment, and a repeat score is typically obtained at 24 hours and at discharge. The scale itself takes a trained examiner roughly 5–10 minutes.
Imaging must be completed and interpreted inside the window as well. Non-contrast CT excludes hemorrhage, which is the absolute contraindication to thrombolysis. CT angiography identifies large vessel occlusion, and CT perfusion or MRI provides the tissue-level data needed for extended-window decisions. The door-to-CT target is 20 minutes in many stroke program protocols.
The 4.5-hour window is not a soft guideline. The original pooled analysis of the major alteplase trials, published in The Lancet in 2014, showed that the benefit of treatment declines steadily with time and that treatment beyond 4.5 hours produced no significant benefit in the overall population. That is why the history-taking has to be structured to reach a go or no-go decision quickly.
The 60-Minute Door-to-Needle Target and How It Structures the Assessment
The 60-minute door-to-needle target is the operational number that most directly answers the time-frame question for a hospital setting. The American Heart Association's Target: Stroke initiative, launched in 2010, set 60 minutes as the goal and later added a 45-minute advanced target. Hospitals that joined the program reported meaningful reductions in door-to-needle times, and the program's published analyses showed that faster treatment was associated with lower in-hospital mortality.
Meeting 60 minutes requires parallel processing rather than sequential processing. The triage nurse obtains the last known well time and activates the stroke team while the patient is still in the ambulance or at the door. Registration happens at the bedside or after treatment. The CT scanner is cleared before the patient arrives. The pharmacist prepares the drug while imaging is underway.
History and neurologic assessment are collected in parallel with these steps. The stroke team member taking the history asks about anticoagulants while the nurse places the IV. The NIH Stroke Scale is performed while the patient is being transferred to the scanner. The family is interviewed by a second team member while the primary clinician examines the patient.
A realistic breakdown of the 60 minutes looks like this: 0–10 minutes for triage, activation, and initial assessment; 10–25 minutes for CT completion; 25–40 minutes for interpretation, lab results, and treatment decision; 40–60 minutes for drug preparation and administration. History and neurologic data collection spans the entire hour rather than occupying a discrete block.
Hospitals that miss the 60-minute target usually fail at one of three points: delayed stroke team activation, delayed CT availability, or delayed decision-making because the history was incomplete. Each of those is a process problem, and each is fixable with protocol design.
Data That Must Be Captured Within 10 Minutes of Arrival
The first ten minutes of a stroke encounter determine whether the rest of the timeline holds. The data collected in this window is limited but non-negotiable, and it should be gathered by whoever reaches the patient first rather than waiting for a specialist.
The immediate data set includes last known well time, current medications with particular attention to anticoagulants, a focused neurologic exam confirming the deficit, blood glucose, and the time the stroke team was activated. Blood glucose is included because hypoglycemia is a stroke mimic, and a fingerstick result of 35 mg/dL changes the entire clinical picture in seconds.
The focused neurologic exam in this window is not the full NIH Stroke Scale. It is a rapid screen for facial droop, arm drift, speech abnormality, and gaze deviation, which can be completed in under two minutes. If the screen is positive, the full scale follows.
The history in this first window should also capture the patient's baseline functional status. A patient who was already bedbound and dependent before the event has a different treatment calculus than one who was independent. This detail is frequently missed in the rush and often has to be reconstructed later from family or nursing home records.
Failure to capture these ten-minute data points reliably is the single most common reason a hospital's median door-to-needle time creeps above 60 minutes. When the stroke team arrives and has to restart the history from scratch, the clock has already burned a third of its budget.
Imaging, Labs, and Consent: What Can Wait and What Cannot
Not all assessment data carries the same urgency, and treating everything as equally time-critical slows the process down. The genuinely non-deferrable items are last known well, anticoagulant status, blood glucose, non-contrast CT, and the NIH Stroke Scale. The deferrable items include the lipid panel, HbA1c, baseline ECG interpretation beyond rhythm, and most of the social history.
The complete blood count and coagulation studies sit in a middle category. Guidelines allow thrombolysis to proceed while waiting for platelet count and INR results in patients who are not on anticoagulants and have no known bleeding disorder, because the results rarely change management in that population. For patients on warfarin, the INR is genuinely decision-critical and should be obtained as a stat point-of-care test.
Consent is a genuine bottleneck that many protocols mishandle. For a patient who cannot consent, the treating clinician may proceed under emergency exception in many jurisdictions, but the exact rule varies. The clinician should document the attempt to reach a surrogate and the clinical rationale for proceeding. Family members who arrive after treatment has started sometimes object, and having the documentation in place protects both the patient and the team.
The practical sequencing is this: glucose and CT first, anticoagulant history and NIHSS in parallel, everything else after the treatment decision. A protocol that requires the full lab panel before treatment will consistently exceed the 60-minute target.
Extended Windows to 24 Hours and the Assessment Burden They Add
Selected patients with large vessel occlusion can be treated with mechanical thrombectomy up to 24 hours from last known well, and this extended window changes what history and assessment data must be obtained. The DAWN trial, published in the New England Journal of Medicine in 2018, enrolled patients 6–24 hours from last known well with clinical-imaging mismatch and showed a substantial benefit from thrombectomy. DEFUSE 3, published in the same journal the same year, extended the evidence to 6–16 hours with perfusion imaging criteria.
The extended window requires perfusion imaging, usually CT perfusion or MRI, to identify salvageable tissue. It also requires a more detailed history because the risk-benefit calculus shifts. Patients on anticoagulants, patients with poor baseline functional status, and patients with large established infarcts are less likely to benefit.
The assessment data in the extended window follows a different priority order. The last known well time is still the anchor, but the interval is measured in hours rather than minutes. The imaging is more elaborate. The history focuses on baseline function and the likelihood of a meaningful recovery.
A patient arriving at hour 12 with a large vessel occlusion and a favorable perfusion profile is a legitimate thrombectomy candidate. A patient arriving at hour 12 with a completed infarct and no salvageable tissue is not. The difference is determined by imaging, which means imaging has to happen before the treatment decision, which in turn means the history must be collected while the imaging is being processed.
The 24-hour window has expanded the population of patients who benefit from rapid assessment, and it has made the initial history more important rather than less. The team needs to know early whether the patient might be a late-window candidate, because that determines whether perfusion imaging is ordered immediately or after the standard CT.
Pediatric and Special Populations Where the Clock Works Differently
Children with suspected stroke present a genuine edge case because the standard adult timelines and treatment windows do not map cleanly onto pediatric care. Pediatric stroke is rare, and the evidence base for thrombolysis and thrombectomy in children is drawn from case series and registry data rather than randomized trials.
The assessment timeline in pediatric stroke is usually longer, not because the clinical urgency is lower but because the differential diagnosis is broader. Stroke mimics in children include migraine, seizure with post-ictal deficit, infection, and metabolic disorders. The history has to rule those out, which takes more time.
The 2019 American Heart Association scientific statement on pediatric stroke management supports consideration of thrombolysis in children within 4.5 hours of onset in centers with pediatric stroke expertise. The statement is careful and conditional, and it emphasizes that pediatric stroke should be managed in consultation with a pediatric neurologist. The timeline in practice is therefore driven by access to that consultation.
Pregnant patients represent another special population. The eligibility criteria for thrombolysis in pregnancy are more cautious, and the assessment must include obstetric history, gestational age, and fetal status. The 4.5-hour window still applies, but the decision requires input from obstetrics as well as neurology.
In both populations, the general principle holds: last known well anchors the clock, and the data must be collected as fast as is safe. The difference is that "as fast as is safe" involves more consultation and more careful history-taking than in the typical adult case.
How Documentation Timing Affects Both Treatment and Legal Defensibility
The timing of documentation matters independently of the timing of assessment, and the two are often confused. The data has to be collected fast, but the documentation must be contemporaneous and accurate. A note written three hours after the fact that omits the last known well time is a problem even if the assessment itself was timely.
Medical-legal review in stroke cases focuses heavily on the timeline. The plaintiff's expert will reconstruct what data was available at what moment, and the defense depends on showing that the assessment was timely and the decision was reasonable given the information available. A missing timestamp for last known well is difficult to defend.
The practical solution is to timestamp each data element as it is collected, whether in the electronic record or on a paper stroke flowsheet. Many stroke programs use a pre-printed flowsheet with fields for last known well, door time, CT time, lab time, and needle time, and the team fills it in as events occur. That flowsheet becomes the primary source for both quality review and any later legal inquiry.
The documentation also protects the clinical team when the decision is to withhold treatment. A patient who arrives at hour six and is not thrombolysed because of the window still requires a full assessment and clear documentation of why treatment was not given. Documentation that says only "outside window" without recording the last known well time, the family interview, and the imaging findings leaves the decision poorly supported.
Common Timing Failures and the Numbers That Expose Them
Several failure modes recur across stroke programs, and each one shows up clearly in the quality data. Recognizing them is the first step toward fixing them, and fixing them is what moves the median door-to-needle time from 75 minutes to 45 minutes.
| Failure mode | Typical symptom | Median time cost |
|---|---|---|
| Stroke team activation delay | Activation >5 minutes after arrival | +15–20 minutes |
| CT scanner unavailable | Scan completed >25 minutes after arrival | +10–15 minutes |
| Incomplete anticoagulant history | Treatment held pending clarification | +20–40 minutes |
| Consent process mishandled | Treatment delayed for surrogate consent | +15–30 minutes |
| No documented last known well | Onset defaulted to arrival time | Treatment denied |
Each row represents a process problem that is solvable. Activation delay is usually fixed by pre-hospital notification and a single-call activation pathway. CT availability is fixed by giving stroke patients priority access to the scanner. Incomplete history is fixed by building the anticoagulant questions into the first-contact checklist.
The consent issue is the most misunderstood. In many jurisdictions, emergency exception allows treatment without consent when delay would risk the patient's life or health. The clinician should know the rule in their jurisdiction and document the emergency rationale. That single piece of preparation removes the most avoidable delay in the entire sequence.
The last row is the most damaging. A patient whose last known well is not established at first contact may be excluded from treatment entirely, not because they were ineligible but because the record did not support eligibility. That is the case where documentation timing and clinical timing diverge most sharply.
FAQ
Can the last known well time be estimated if no witness is available?
The last time the patient was seen normal is the only defensible onset marker, and if that is the last time a family member saw them, it is the onset. Documenting an estimated onset without a witness basis is risky, and the WAKE-UP imaging protocol exists specifically to identify patients with unwitnessed onset who may still benefit from treatment. The imaging result becomes the eligibility criterion when the history cannot supply one.
Is the 60-minute door-to-needle target a hard rule or a performance benchmark?
It is a benchmark, and many centers do not meet it on every case. Hospitals in the American Heart Association's Get With The Guidelines–Stroke program track the metric publicly and use it for internal quality improvement, but individual cases routinely exceed it without any regulatory consequence. The clinical urgency of the target comes from the evidence that earlier treatment produces better outcomes, not from any enforcement mechanism.
What is the difference between the 4.5-hour window and the 24-hour window?
The 4.5-hour window is the standard intravenous thrombolysis window, and it applies to eligible patients without advanced imaging selection. The 24-hour window applies specifically to mechanical thrombectomy in selected patients with large vessel occlusion and favorable perfusion imaging, based on the DAWN and DEFUSE 3 trials. Patients outside the thrombolysis window may still be candidates for thrombectomy, which is why the assessment does not stop when the drug window closes.
Does the assessment timeline differ for posterior circulation stroke?
Posterior circulation stroke presents with symptoms such as vertigo, diplopia, ataxia, and dysarthria rather than the classic facial droop and arm weakness, and the diagnosis is more often missed at first contact. The time windows are the same, but the history has to probe for those symptoms specifically, and the NIH Stroke Scale captures them less well than anterior circulation deficits. The assessment should include specific questions about vision, swallowing, and gait.
Can a patient who wakes with symptoms still receive thrombolysis?
Yes, in some cases, using imaging-based selection rather than time-based selection. The WAKE-UP trial used DWI-FLAIR mismatch on MRI to identify wake-up stroke patients who benefited from alteplase, and centers with access to that protocol may treat patients outside the standard 4.5-hour window. The assessment in those cases includes MRI in addition to CT, which adds time but also enables treatment that would otherwise be withheld.
What is the cost of a delayed stroke assessment?
Apart from the clinical harm, which is the primary cost, a delayed assessment carries measurable hospital costs. Prolonged door-to-needle times are associated with longer lengths of stay, greater need for post-acute rehabilitation, and higher rates of institutional discharge, according to analyses published in the journal Stroke. Quality improvement programs that reduce median door-to-needle time produce measurable savings in downstream care, though attributing specific dollar figures requires facility-level cost accounting.
Who should be consulted when the treatment decision is unclear?
A stroke neurologist or neurointerventionalist should be the final decision-maker in uncertain cases, and most programs have a 24/7 consultation line for exactly this scenario. The treating emergency physician should not be expected to make the call alone when the history is ambiguous or the imaging is borderline. Documenting the consultation and the rationale is part of the record that later review will examine.
This article provides general educational information about stroke assessment timelines and is not a diagnosis, treatment plan, or substitute for individualized clinical judgment. Stroke care must be directed by a qualified local clinician who can examine the patient and access the appropriate imaging and consultation. If you or someone else is showing signs of stroke, call emergency services immediately rather than waiting to read more.